Insuman Comb 30 (Insulin Human)

Insulin Human mimics natural human insulin by binding to insulin receptors on muscle, fat and liver cells. This triggers cellular pathways that increase glucose uptake, promote glycogen storage, and suppress hepatic glucose production, thereby lowering circulating blood sugar.

The dose of Insuman Comb 30 is individualized. A qualified prescriber determines the total daily insulin requirement, the proportion of basal versus prandial insulin, and the injection schedule based on the patient’s blood‑glucose targets, diet, activity level and clinical response.

Insulin is generally considered the treatment of choice for diabetes in pregnancy because it does not cross the placenta. However, the decision to use Insuman Comb 30 during pregnancy or while breastfeeding should be made by a healthcare professional after evaluating maternal and fetal risks and benefits.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Insuman Comb 30 is a premixed 30/70 formulation, meaning it contains 30% rapid‑acting and 70% intermediate‑acting insulin. This differs from basal‑only insulins (e.g., glargine) or rapid‑acting only insulins (e.g., lispro). The premixed format offers convenience for patients who prefer fewer daily injections but provides less flexibility for precise basal‑prandial adjustments.

Insuman Comb 30 should be stored in a refrigerator at 2‑8 °C, protected from light. Do not freeze or shake the vial. Once in use, it may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, after which any remaining insulin should be discarded.

Insuman Comb 30 is administered by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection site should be rotated to avoid lipodystrophy. Patients should follow their prescriber’s instructions regarding dose timing relative to meals and monitor blood glucose regularly.

The most serious risks include severe hypoglycaemia, which can lead to loss of consciousness or seizures, and allergic reactions ranging from rash to anaphylaxis. Patients should be educated on recognizing early signs of hypoglycaemia and instructed to seek immediate medical attention for any suspected allergic response.

Insuman Comb 30 is contraindicated in individuals with a known hypersensitivity to insulin human or any excipients in the formulation. It should also be avoided in patients with severe hypoglycaemia unawareness or those who cannot reliably monitor blood glucose levels.